Technology
Health
Pharmaceutical

Sage Therapeutics

$184.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.28 (-0.69%) Today
$0.00 (0.00%) As of 4:28 PM EDT after-hours

Why Robinhood?

You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!

About SAGE

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Employees
637
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
9.42B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
352.37K
High Today
$187.70
Low Today
$183.90
Open Price
$186.29
Volume
286.54K
52 Week High
$193.56
52 Week Low
$79.88

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2014 IPO
US

SAGE Earnings

-$3.38
-$2.37
-$1.37
-$0.36
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.